Research programme: small molecule cancer therapeutics - FORMA Therapeutics/Nanosyn

Drug Profile

Research programme: small molecule cancer therapeutics - FORMA Therapeutics/Nanosyn

Alternative Names: Epigenetics cancer therapeutics; Protein homeostatis cancer therapeutics

Latest Information Update: 31 Jul 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FORMA Therapeutics; Nanosyn
  • Class Small molecules
  • Mechanism of Action Deubiquitinating enzyme modulators; Histone acetyltransferase modulators; Histone deacetylase modulators; Histone demethylase modulators; Histone methyltransferase modulators; Protein modulators; Ubiquitin protein ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 29 Jul 2014 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top